

Please complete the ABSTRACT TEMPLATE online, for Biomed 2023 Company Presentations

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

All items marked with an * are mandatory to complete
The maximum number of words for this abstract is 400

Please be sure to complete the following:

Company name Gilboa Therapeutics LTD * Website www.gilboa.bio *

CEO name Mr. Barry Labinger * Cell phone number +1-301-768-8260 *

Select a CATEGORY: Biotech/Pharma or Medical Devices or Health IT/Digital *
(Delete categories you are not selecting)

Select up to two SESSIONS per abstract from the list below *

(Delete sessions you are not selecting)

3. Are Cancer Therapeutics Fulfilling the Promise?

You may delete the section instructions, leaving **only the bolded bullet title**
Answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational**
Gilboa Tx is a pre-clinical stage biotech company developing a breakthrough T cell therapy for solid cancers, that overcomes the inherent limitations of CAR T cells. These novel engineered T-cells, called **SolidT**, show effective and specific cytotoxicity only towards tumor cells, sparing normal tissues expressing low antigen levels, thus providing a favorable safety profile.
- **Core Technology**
Peripheral blood T cells engineered with Gilboa's novel receptor, based on the high-affinity FcγRI scaffold, allowing T-cells to target solid tumor cells using antibody intermediates. This breakthrough technology manifests remarkable killing abilities against solid tumors in mouse models with an unprecedented safety profile.
- **Product Profile/Pipeline**
Gilboa Tx is developing an extensive pipeline, including off-the-shelf **SolidT** based on engineered γ/δ T cells, next-generation **SolidT** that target HER2 +1 tumors, and developing new combinations with proprietary antibodies to target diseases with urgent unmet medical need.
- **Business Strategy**
The SolidT technology is an autologous cell therapy that will be developed as a therapeutic product in combination with relevant mAbs.
- **What's Next?**
Round A funding, CMC activities and IND-enabling studies for our lead program toward Phase I clinical trial.

